ATE216230T1 - Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen - Google Patents

Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen

Info

Publication number
ATE216230T1
ATE216230T1 AT00907510T AT00907510T ATE216230T1 AT E216230 T1 ATE216230 T1 AT E216230T1 AT 00907510 T AT00907510 T AT 00907510T AT 00907510 T AT00907510 T AT 00907510T AT E216230 T1 ATE216230 T1 AT E216230T1
Authority
AT
Austria
Prior art keywords
fatty acids
essential fatty
dha
epa
patient
Prior art date
Application number
AT00907510T
Other languages
English (en)
Inventor
Franco Pamparana
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11381919&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE216230(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Application granted granted Critical
Publication of ATE216230T1 publication Critical patent/ATE216230T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00907510T 1999-02-17 2000-02-07 Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen ATE216230T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000313A IT1308613B1 (it) 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
PCT/EP2000/000957 WO2000048592A1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events

Publications (1)

Publication Number Publication Date
ATE216230T1 true ATE216230T1 (de) 2002-05-15

Family

ID=11381919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907510T ATE216230T1 (de) 1999-02-17 2000-02-07 Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen

Country Status (26)

Country Link
US (2) US7462643B1 (de)
EP (2) EP1247523A1 (de)
JP (2) JP5441287B2 (de)
KR (2) KR20070098954A (de)
CN (1) CN1230159C (de)
AT (1) ATE216230T1 (de)
AU (1) AU775078B2 (de)
BR (1) BR0008153A (de)
CA (1) CA2362271C (de)
CZ (1) CZ301307B6 (de)
DE (1) DE60000133C5 (de)
DK (1) DK1152755T3 (de)
EA (1) EA004312B1 (de)
ES (1) ES2174814T3 (de)
HK (1) HK1044720B (de)
HU (1) HUP0200111A3 (de)
ID (1) ID30205A (de)
IL (2) IL144377A0 (de)
IT (1) IT1308613B1 (de)
NO (1) NO328797B1 (de)
NZ (1) NZ513093A (de)
PL (1) PL209078B1 (de)
PT (1) PT1152755E (de)
SK (1) SK286523B6 (de)
WO (1) WO2000048592A1 (de)
ZA (1) ZA200106029B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
CA2485116C (en) 2002-05-03 2013-02-05 Pronova Biocare As Use of epa and dha in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
DE602005026582D1 (de) 2005-03-11 2011-04-07 Recon Oil Ind Private Ltd Synergistisch hitzestabiles ölmedium mit eicosapentaensäure (epa) und docosahexaensäure (dha)
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
ES2489741T3 (es) * 2005-07-08 2014-09-02 Mochida Pharmaceutical Co., Ltd. Composición para la prevención de la aparición de acontecimientos cardiovasculares
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
AU2006327064B2 (en) * 2005-12-21 2012-04-26 Brudy Technology, S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US7498359B2 (en) 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
CA2653787C (en) 2006-05-31 2016-06-21 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of cardiovascular event in multiple risk patient
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
CA2732071C (en) 2008-08-07 2018-02-13 Claudio Cavazza Long-term use of n-3 pufa in the treatment of symptomatic heart failure
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
EP2475309A4 (de) * 2009-09-08 2015-07-29 Atrium Medical Corp Herniapflaster
ES2862980T3 (es) 2009-12-30 2021-10-08 Basf Pharma Callanish Ltd Composiciones de ácido graso poliinsaturado obtenibles mediante un proceso de separación cromatográfica en lecho móvil simulado
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
KR101681907B1 (ko) * 2012-02-27 2016-12-12 주식회사 케어사이드 혈액 순환 촉진 및 피부 질환 개선용 조성물
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
CN104321053A (zh) 2012-03-30 2015-01-28 桑茨利奥&孔帕尼股份有限公司 ω-3脂肪酸酯组合物
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
WO2014057362A2 (en) * 2012-09-24 2014-04-17 Aker Biopharma As Omega -3 compositions
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
EP3118186B1 (de) 2013-12-11 2022-02-09 Novasep Process Chromatografische anlage zur herstellung von mehrfach ungesättigten fettsäuren
US10975031B2 (en) 2014-01-07 2021-04-13 Novasep Process Method for purifying aromatic amino acids
PL237374B1 (pl) * 2017-11-10 2021-04-06 Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
NO157302C (no) 1985-12-19 1988-02-24 Norsk Hydro As Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
JP2893866B2 (ja) 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5324323A (en) 1992-09-09 1994-06-28 Telectronics Pacing Systems, Inc. Multiple channel cardiosynchronous myoplasty apparatus
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
AU685767B2 (en) 1992-12-11 1998-01-29 Novartis Ag Substituted benzazepinones
CN1082909A (zh) 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH07118229A (ja) 1993-10-19 1995-05-09 Fujisawa Pharmaceut Co Ltd 尿素誘導体およびその製造法
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JPH0812581A (ja) 1994-06-30 1996-01-16 Fujirebio Inc 虚血性心疾患治療剤
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6333447B1 (en) 1996-03-29 2001-12-25 The General Hospital Corporation Transgenic model of heart failure
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
DE69737062T2 (de) 1996-09-05 2007-07-12 The Regents Of The University Of California, Oakland Gentherapie für kongestives herzversagen
WO1998057628A1 (fr) 1997-06-16 1998-12-23 Nippon Suisan Kaisha, Ltd. Composition capable de supprimer le facteur de risque pendant l'exercice
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1130027A1 (de) 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben

Also Published As

Publication number Publication date
PT1152755E (pt) 2002-09-30
KR20070098954A (ko) 2007-10-05
ES2174814T3 (es) 2002-11-16
PL209078B1 (pl) 2011-07-29
IT1308613B1 (it) 2002-01-09
HK1044720A1 (en) 2002-11-01
CA2362271C (en) 2008-07-15
CA2362271A1 (en) 2000-08-24
WO2000048592A1 (en) 2000-08-24
HUP0200111A3 (en) 2003-03-28
ZA200106029B (en) 2002-09-25
JP2010116414A (ja) 2010-05-27
CZ301307B6 (cs) 2010-01-06
IL144377A (en) 2006-12-10
NO328797B1 (no) 2010-05-18
SK286523B6 (sk) 2008-12-05
CN1230159C (zh) 2005-12-07
EP1152755B1 (de) 2002-04-17
HUP0200111A2 (hu) 2002-05-29
NZ513093A (en) 2003-02-28
HK1044720B (zh) 2006-08-18
DK1152755T3 (da) 2002-07-22
CZ20012947A3 (cs) 2002-04-17
EP1247523A1 (de) 2002-10-09
EA004312B1 (ru) 2004-02-26
US20090018193A1 (en) 2009-01-15
AU775078B2 (en) 2004-07-15
NO20013938L (no) 2001-08-14
EP1152755A1 (de) 2001-11-14
BR0008153A (pt) 2001-11-06
SK10802001A3 (sk) 2001-12-03
AU2907500A (en) 2000-09-04
DE60000133C5 (de) 2014-02-27
PL350851A1 (en) 2003-02-10
JP2002537252A (ja) 2002-11-05
NO20013938D0 (no) 2001-08-14
CN1343120A (zh) 2002-04-03
KR20010102183A (ko) 2001-11-15
DE60000133D1 (de) 2002-05-23
KR100823051B1 (ko) 2008-04-18
JP5441287B2 (ja) 2014-03-12
EA200100895A1 (ru) 2002-02-28
ITMI990313A1 (it) 2000-08-17
IL144377A0 (en) 2002-05-23
ID30205A (id) 2001-11-15
US7462643B1 (en) 2008-12-09
DE60000133T2 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
ATE216230T1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
US5198468A (en) Essential fatty acid composition
ES2117390T3 (es) Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
KR940018090A (ko) 트리글리세라이드
DE69720787D1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
IL153458A0 (en) Therapeutic combinations of fatty acids
ATE361066T1 (de) Polyungesättigen fettsäuren nährungsergänzung
PT1310249E (pt) Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves
DE69328618D1 (de) Medikamente auf der Basis von Docosahexaensäure, als Plättchenaggregationshemmer und gegen cerebralen Mangel an Fettsäuren, und Verfahren zur Herstellung.
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
UA94693C2 (ru) Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, которые страдают сердечно-сосудистым заболеванием
HUP0000419A2 (hu) Eikozapentaénsavat és/vagy sztearidonsavat tartalmazó gyógyászati készítmény
RU94002318A (ru) Триглицериды
RU99109049A (ru) Фармацевтический препарат, содержащий эйкозапентаеновую кислоту и/или стеаридоновую кислоту

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1152755

Country of ref document: EP